Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

6.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K
RNA Interference01:23

RNA Interference

26.5K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.5K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
Types of RNA01:23

Types of RNA

65.0K
Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
65.0K
Leaky Scanning02:28

Leaky Scanning

5.2K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.2K
Translational Regulation01:29

Translational Regulation

99
Translational regulation in prokaryotes ensures efficient protein synthesis by controlling ribosome access to mRNA. This regulation is mediated by secondary RNA structures, including translational riboswitches, RNA thermometers, and small RNAs (sRNAs), which respond to intracellular and environmental signals to modulate gene expression.Translational RiboswitchesRiboswitches in the leader region of mRNAs can regulate translation by altering the accessibility of the Shine-Dalgarno (SD) sequence,...
99

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Environmental surveillance of enteric viruses in mussels reveals reduced contamination during the pandemic restriction period.

Environmental pollution (Barking, Essex : 1987)·2026
Same author

In silico characterisation of a novel SARS-CoV-2 envelope protein inhibitor and in vitro validation against murine coronavirus.

Bioorganic chemistry·2026
Same author

A Newcastle disease outbreak in backyard and free-range poultry in Slovenia.

Frontiers in veterinary science·2026
Same author

Immune response in dogs with myxomatous mitral valve disease: insights into monocyte and lymphocyte subtypes and natural killer cells.

Journal of veterinary internal medicine·2026
Same author

Advances in Clostridioides difficile research: Insights from the 8th International C. difficile symposium (ICDS 2024).

Anaerobe·2026
Same author

A case study of critical points for the entry and spread of Salmonella Infantis in a broiler farm.

Irish veterinary journal·2026

Related Experiment Video

Updated: Sep 14, 2025

Peptide-based Identification of Functional Motifs and their Binding Partners
14:28

Peptide-based Identification of Functional Motifs and their Binding Partners

Published on: June 30, 2013

12.6K

Different SARS-CoV-2 variants inhibited by RRM designed peptide.

Uros Krapez1, Urska Kuhar2, Petra Šenica2

  • 1Institute for Poultry, Birds, Small Mammals, and Reptiles, Veterinary Faculty, University of Ljubljana, Ljubljana, Slovenia.

Plos One
|July 22, 2025
PubMed
Summary

The Resonant Recognition Model designed peptide CovA effectively targets multiple SARS-CoV-2 variants, offering a promising, variant-independent approach for COVID-19 drug development.

More Related Videos

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
07:53

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation

Published on: January 9, 2019

33.3K
Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.5K

Related Experiment Videos

Last Updated: Sep 14, 2025

Peptide-based Identification of Functional Motifs and their Binding Partners
14:28

Peptide-based Identification of Functional Motifs and their Binding Partners

Published on: June 30, 2013

12.6K
A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
07:53

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation

Published on: January 9, 2019

33.3K
Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.5K

Area of Science:

  • Virology
  • Drug Discovery
  • Computational Biology

Background:

  • SARS-CoV-2 variants emerge with potentially altered transmissibility and severity.
  • A need exists for COVID-19 treatments less susceptible to viral mutations.
  • Previous research designed peptide CovA using the Resonant Recognition Model (RRM) to block viral entry via ACE2.

Purpose of the Study:

  • To evaluate the efficacy of RRM-designed peptide CovA against diverse SARS-CoV-2 variants.
  • To explore the potential of RRM-based strategies for developing variant-independent antiviral therapies.

Main Methods:

  • Utilized the Resonant Recognition Model (RRM) to identify conserved SARS-CoV-2 characteristics.
  • Designed de novo peptide CovA based on RRM findings.
  • Tested CovA's inhibitory activity against multiple SARS-CoV-2 variants using cell culture models and inhibitor screening assays.

Main Results:

  • Peptide CovA demonstrated activity against all tested SARS-CoV-2 variants.
  • The efficiency of CovA varied across different viral variants.
  • The study confirmed CovA's ability to inhibit viral replication and ACE2 interaction.

Conclusions:

  • The RRM is a powerful tool for designing de novo bioactive peptides with specific biological functions.
  • Peptide CovA shows potential as a broad-spectrum therapeutic agent against SARS-CoV-2, irrespective of variant.
  • This research supports the development of novel COVID-19 drugs with reduced susceptibility to viral evolution.